Progression-free survival
Fig. 2 · Panel Progression-free_survival_in_the_full_analysis_set
Panel Progression-free_survival_in_the_full_analysis_set 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Wenjing Wu, Yaping Yang, Haizhu Chen, Yongkui Lu, Yinduo Zeng, Jianli Zhao, Caiwen Du, Ying Lin, Peijian Peng, Mei Huang, Ying Zhang, Quchang Ouyang, Linxiaoxiao Ding, Ziliang Cheng, Yuanyu Wen, Zhiyong Wu, Jinhui Ye, Li Ling, Kun Wang, Ying Lu, Guorong Zou, Jincai Zhong, Hong Wang, Daren Lin, De Zeng, Chengcai Yao, Qianjun Chen, Liqun Zou, Shusen Wang, Yunfang Yu, Zhongyu Yuan, Ying Wang, Herui Yao
Signal Transduct Target Ther 11(1) 191
Maintenance therapy is key in prolonging remission and improving quality of life for hormone receptor-positive (HR + ), HER-2 negative (HER2-) metastatic breast cancer (MBC), but optimal strategies remain debated. This multicenter, open-label, randomized phase 3 trial conducted across 22 hospitals in mainland China (ClinicalTrials.gov, NCT04263298; Chinadrugtrials.org.cn, ChiCTR-IIR-17014036) compared the efficacy and safety of fulvestrant versus capecitabine as maintenance therapy in HR + /HER2- MBC patients after achieving objective response or disease control following first-line chemotherapy. The primary end point was investigator-assessed progression-free survival (PFS). A total of 210 patients underwent randomization, with 105 assigned to each group. As of the data cutoff date on March 1, 2025, the median follow-up was 33.6 months (range 1.5-81.1). Median PFS favored fulvestrant compared with capecitabine (17.3 months [95% CI 12.7-23.3] vs. 9.0 months [95% CI 7.5-14.3]; hazard ratio 0.63, 95% CI 0.47-0.99; p = 0.003). Overall survival data were not yet mature. Grade ≥3 adverse events (AEs) occurred in three patients (2.9%) in the fulvestrant group and 11 (10.5%) in the capecitabine group. Treatment discontinuation due to AEs occurred in 0% and 7.6% of patients, respectively. Fulvestrant maintenance therapy significantly improves PFS compared to capecitabine in HR + /HER2- MBC patients achieving objective response or disease control following first-line chemotherapy, with a favorable safety profile.
2 个 Figure · 3 个 KM 面板
Fig. 2 Progression-free survival in the full analysis set. Note: The short vertical lines represent censored data
Fig. 2 · Panel Progression-free_survival_in_the_full_analysis_set
Panel Progression-free_survival_in_the_full_analysis_set 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 Total progression-free survival (tPFS) and total overall survival (tOS) in the full analysis set. a tPFS; b tOS. The short vertical lines represent censored data. Note: tPFS was defined as the time from initiation of first-line chemotherapy to disease progression, death, or the latest follow-up. tOS was defined as the time from initiation of first-line chemotherapy to death from any cause or the latest follow-up
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel B
Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。